



**Suitability Petition  
Completeness Assessment Correspondence**

Lachman Consultant Services, Inc.  
1600 Stewart Avenue, Suite 604  
Westbury, NY 11590  
Attn: Martin Shimer

Sent via email to: [m.shimer@lachmanconsultants.com](mailto:m.shimer@lachmanconsultants.com)

Docket No. FDA-2024-P-3905

Dear Martin Shimer:

This is in reference to your petition received on August 15, 2024, by the U.S. Food and Drug Administration (FDA or Agency), requesting permission, in accordance with 21 C.F.R. §314.93(b), to submit an Abbreviated New Drug Application (ANDA) for the following drug product: Estradiol Vaginal Inserts, 1 g and 2 g. The petition was examined for initial completeness (i.e. Completeness Assessment) under CFR 10.30 and the Agency has made a threshold determination that the petition is complete.

This petition is subject to the provisions of the Generic Drugs User Fee Amendments of 2022 (GDUFA III) whereby any suitability petitions submitted in FY 2024-2027 will receive a goal date of 6 months after the completeness assessment. The GDUFA goal date for review of this petition is February 28, 2025.

If you have any questions, contact [ANDAFiling@fda.hhs.gov](mailto:ANDAFiling@fda.hhs.gov).

A copy of this letter will be placed on public display in the Dockets Management Branch, Room 1061, Mail Stop HFA-305, 5630 Fishers Lane, Rockville, MD 20852.

Sincerely,

*{See appended electronic signature page}*

Bijal Patel, Pharm.D., BCPS  
Team Leader  
Division of Filing Review  
Office of Regulatory Operations  
Office of Generic Drugs  
Center for Drug Evaluation and Research



Bijal  
Patel

Digitally signed by Bijal Patel

Date: 8/30/2024 01:17:00PM

GUID: 592d8091002ee5f4d369b202419a91e9